7 employees
OctreoPharm Sciences is focused on the development of new radio pharmaceuticals for neuroendocrine tumors.
2009
$7.2M
from 2 investors over 2 rounds
OctreoPharm Sciences GmbH raised $7.2M on April 12, 2011
Investors: IBB Beteiligungsgesellschaft mbH and KfW